An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia

Trial Profile

An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Lirilumab (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results (n=25) assessing safety and preliminary efficacy of lirilumab with azacytidine in relapsed AML patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Dec 2016 Results (n=21) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Dec 2016 Results published in the Innate Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top